Mealtime fast-acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin-resistant Type 2 diabetes.

Keith BoweringJ HarveyJ W KolaczynskiJ W SnyderB W Bode

Published in: Diabetic medicine : a journal of the British Diabetic Association (2018)

Fast-acting insulin aspart may hold promise as a more effective treatment compared with insulin aspart for controlling PPG in people with insulin-resistant Type 2 diabetes.

Keyphrases

type diabetes
glycemic control
cardiovascular disease
insulin resistance
metabolic syndrome
blood pressure
adipose tissue
deep learning